ArticleJHEP reports : innovation in hepatology2026

Pembrolizumab and stereotactic body radiotherapy combined in advanced hepatocellular carcinoma post sorafenib - A phase II trial (PEMRAD).

Grainne M O'Kane et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.